Introduction
============

Resistant hypertension (RH) is defined as blood pressure (BP) that remains above goal, despite concurrent use of three antihypertensive agents from different classes. Ideally, one of these three agents should be a diuretic, and all agents should be prescribed at optimal doses.[@b1-cia-9-1495] RH is a common clinical condition and is associated with increased cardiovascular mortality and morbidity.

The prevalence of RH is difficult to estimate because there have been few relevant prospective studies. However, a recent study reported a 12.8% prevalence of RH among the antihypertensive drug-treated population in the USA.[@b2-cia-9-1495] Many RH-related issues remain unclear because of difficulties in selecting patients with true isolated RH. In selected RH patients, renal denervation has been shown to control BP by suppressing sympathetic nervous system overactivity. Treatment of RH should focus on pathophysiological mechanisms that prevent good hypertensive control. As a result of concurrent conditions such as diabetes, chronic kidney disease, sleep apnea, and coronary artery disease, this population remains difficult to study with regard to etiology and treatment efficacy. Arterial stiffening (AS) independently predicts cardiovascular events in patients with hypertension[@b3-cia-9-1495]--[@b5-cia-9-1495] and in those with diabetes mellitus.[@b6-cia-9-1495] Elevated AS is associated with complex coronary artery disease,[@b7-cia-9-1495] as well as numerous cardiovascular risk factors, including age, hypertension, diabetes mellitus, and end-stage renal disease.[@b8-cia-9-1495],[@b9-cia-9-1495] Brachial-ankle pulse wave velocity (baPWV) is the gold standard method for measuring AS.[@b10-cia-9-1495] AS and RH share similar associated characteristics, including older age, isolated systolic hypertension, chronic kidney disease, diabetes, left ventricular hypertrophy, female sex, obesity, and excessive dietary salt intake.[@b11-cia-9-1495] To the authors' knowledge, only one previous study has investigated the role of AS in RH.[@b12-cia-9-1495] Thus, our study may be the first to determine an association between RH and AS by evaluation of baPWV.

Materials and methods
=====================

Participants and study design
-----------------------------

This observational study was conducted between April 2011 and December 2013. Patients were either referred or self-referred to the outpatient hypertension unit at a single cardiovascular center. The study was approved by the local ethics committee. A total of 1,336 consecutive patients were diagnosed with essential hypertension, and 284 normotensive patients were also entered into the study. Patients were selected according to the following inclusion criteria: age ≥65 years; hypertension, defined as at least three measurements of office systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg in a sitting position, or previously diagnosed and receiving antihypertensive medication; and normal sinus rhythm. Individuals were excluded if they had any of the following: secondary causes of hypertension, established kidney failure (estimated glomerular filtration rate \<15 mL/min/1.73 m^2^), diagnosed atrial fibrillation, physical or mental impairment, or inability to perform home BP measurement.

Each subject then underwent a comprehensive patient history and physical examination. All subjects were monitored for home BP, body mass index, and waist and hip circumference. Blood samples were obtained for all participants following an overnight fast and prior to taking any medications. baPWV measurements and echocardiography studies were performed within 1 week of the initial evaluation. Patients were divided into three groups. The diagnostic definition for RH has been detailed previously. Control subjects were selected from those without hypertension or any other exclusion criteria (group 1, n=284). Those with normal BP levels on treatment with less than three drugs were defined as the hypertension group (group 2, n=1,194). Patients who fulfilled the criteria for RH were selected as the RH group (group 3, n=142).

BP measurement method
---------------------

A clinically validated automatic electronic device (M10-IT; Omron, Tokyo, Japan) was used for all home BP measurements. Patients were instructed on the home BP measurement technique in a 20-minute training session with their nurse. At the end of the session, patients tested the home BP measurement technique through three consecutive self-measurements taken in the presence of the nurse. The patients monitored their BP at home over a 4-day period, taking three morning measurements (every 2 minutes between 6 am and 9 am) and three evening measurements (between 6 pm and 9 pm). The home BP readings were recorded and stored in the device. Mean home BP was calculated by discarding values obtained on the first day as well as the first measurement obtained each morning and evening. The BP measurement protocol was repeated every 3 months over a 1-year period.

Strategy for reaching goal BP
-----------------------------

The main hypertension treatment objective was to attain and maintain the desired BP goal. Start with one drug then add a second drug before achieving the maximum recommended dose of the initial drug, then titrate both drugs up to the maximum recommended doses of both to achieve goal BP. If goal BP could not be reached with two drugs, both drugs were titrated up to the maximum recommended doses. If the BP goal was not achieved with two drugs, a third drug including a diuretic was selected specifically to avoid combined angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use. The third drug was titrated up to the maximum recommended dose to achieve the BP goal (home daytime mean BP \<135/85 mmHg).

Definitions
-----------

Diabetes mellitus was defined as a previously diagnosed condition, prescribed diet, use of antidiabetic medication, or a fasting venous blood glucose level of ≥126 mg/dL on two occasions. Dyslipidemia was defined as a previously diagnosed condition, use of lipid-lowering agents, elevated plasma total cholesterol (≥200 mg/dL) and/or triglycerides (≥150 mg/dL), or a low high-density lipoprotein level \<40 mg/dL.

Assessment of aortic stiffness
------------------------------

baPWV was measured using a volume-plethysmographic apparatus (Form/ABI; Colin Co Ltd., Komaki, Aichi, Japan). The methodology details have been previously described.[@b13-cia-9-1495] Briefly, this device simultaneously measures bilaterally formed brachial and tibial arterial pressure waves, the lead I electrocardiogram, and a phonocardiogram. With the patient in the supine position, occlusion cuffs were connected to both plethysmographic and oscillometric sensors that were placed around both arms and ankles. All cuffs were then inflated until the brachial and tibial arteries were completely occluded and deflated. Arterial pressure waveforms were digitized at 1,200 Hz for brachial arterial pressure waves and at 240 Hz for tibial arterial pressure waves. Time differences between brachial and ankle arterial pressure waves (ΔT) were examined according to wave front velocity theory. Distances between the brachium and ankle (D) were calculated based on anthropometric data for the Japanese population. Finally, the baPWV was calculated as D/ΔT, thereby not only reflecting aortic stiffness but also leg muscular artery stiffness. Thus, the baPWV is a global AS measure reflecting both elastic and muscular arterial properties.

Echocardiographic studies
-------------------------

Patients were then taken to the echocardiography laboratory and imaged in the left lateral decubitus position using a Philips iE33 ultrasound system (Philips Healthcare Systems, Eindhoven, the Netherlands) equipped with a multifrequency transducer. A complete echocardiographic study was performed using standard views and techniques. M-mode echocardiograms were obtained by two-dimensional guided echocardiography using a transducer with frequency range of 3--5 MHz. The mean of two M-mode measurements obtained by two different investigators was used. Left ventricular mass was subsequently calculated using Devereux's method.[@b14-cia-9-1495] The left ventricular mass index was calculated as the left ventricular mass divided by body surface area.

Statistical analysis
--------------------

Numeric data are presented as the mean and standard deviation and categoric data are presented as frequencies and percentages. One-way analysis of variance and chi-square tests were used for comparisons between the three groups. A multivariate logistic regression analysis was carried out for assessing odds ratios for factors related to the three groups. A receiver operating characteristic (ROC) curve was then used to show a positive correlation between baPWV and RH. Cut-off values were determined as the sum of sensitivity and specificity. The statistical analysis was performed using Statistical Package for the Social Sciences version 20.0 software (IBM Corp., Armonk, NY, USA). A *P*-value \<0.05 was considered to be statistically significant.

Results
=======

Among the 1,620 patients enrolled in this study, 284 were defined as normotensive (group 1); 1,194 patients on treatment with less than three drugs were defined as the hypertension group (group 2); and 142 patients were defined as the RH group (group 3). The baseline characteristics of the study population and of each patient group are summarized in [Table 1](#t1-cia-9-1495){ref-type="table"}. Group 1 (normotensive individuals) contained a higher proportion of men, and showed a lower mean body mass index as well as lower rates of diabetes mellitus, smoking, dyslipidemia, cerebral vascular accident, metabolic syndrome, left atrial enlargement, and left ventricular hypertrophy than the other groups. Group 1 individuals also had lower systolic BP, diastolic BP, and baPWV than the other groups. No differences in age, body surface area, or proportion of individuals with chronic obstructive pulmonary disease was seen between the three groups. Group 3 subjects had higher systolic BP, diastolic BP, and baPWV than the other two groups. The laboratory results are summarized in [Table 2](#t2-cia-9-1495){ref-type="table"}. Group 1 had a lower left ventricular end diastolic diameter, lower left ventricular end systolic diameter, lower interventricular septum diameter, lower left ventricular mass index, and higher aortic root diameter than the other groups. No differences in total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, serum creatinine, estimated glomerular filtration rate, glycated hemoglobin, uric acid, left ventricular ejection fraction, posterior wall diameter, and left atrium diameter were noted between the groups. However, hemoglobin levels were significantly lower in group 3 than in group 1.

Major antihypertensive and antihyperlipidemic drug categories are summarized in [Table 3](#t3-cia-9-1495){ref-type="table"}. The frequently prescribed antihypertensive agents were angiotensin receptor blockers and calcium channel blockers. In group 3, 57% of patients used diuretics, and statins were used by 22.7% of patients in group 2 and 29.6% of those in group 3 (not statistically significant).

We carried out multivariate logistic regression analysis in order to identify factors related to successful BP control (group 2, [Tables 4](#t4-cia-9-1495){ref-type="table"} and [5](#t5-cia-9-1495){ref-type="table"}). Systolic BP significantly correlated with the existence of the normotensive group when compared to the BP controlled group (odds ratio 0.915, 95% confidence interval \[CI\] 0.839--0.997, *P*=0.043). The proportion of diabetes mellitus significantly correlated with the RH group more than the BP controlled group (odds ratio 2.114, 95% CI 1.194--3.744, *P*=0.010). Systolic BP significantly correlated more with the RH group than with the BP-controlled group (odds ratio 1.032, 95% CI 1.012--1.053, *P*=0.001). The baPWV (odds ratio 1.084, 95% CI 1.016--1.156, *P*=0.015) significantly correlated with RH existence. The other factors correlated negatively with the presence of RH.

Comparison of baPWV according to patient group is shown in [Figure 1](#f1-cia-9-1495){ref-type="fig"}. A significant increase in baPWV was observed in the hypertensive groups (groups 2 and 3). The highest baPWV was in group 3. The ROC curve analysis for the relationship between baPWV and RH is shown in [Figure 2](#f2-cia-9-1495){ref-type="fig"}.

Using the ROC curve, we determined the optimal cut-off value of baPWV that could predict the presence of RH ([Figure 2](#f2-cia-9-1495){ref-type="fig"}). The cut-off value of baPWV, which was set at 1,803 cm per second, had a sensitivity of 63.4%, a specificity of 67.2%, and an area under the ROC curve of 0.687 in predicting RH.

Discussion
==========

According to the Framingham Heart Study, approximately 60% of the population has hypertension by the age of 60 years, and about 65% of men and about 75% of women have the disease by 70 years. The elderly are also more likely to suffer from the complications of high BP and are more likely to have uncontrolled hypertension. Compared with younger patients with similar BP, elderly hypertensive patients have lower cardiac output, higher peripheral resistance, wider pulse pressure, lower intravascular volume, and lower renal blood flow. These age-related pathophysiological changes must be considered when treating hypertension in the elderly. Most elderly hypertensive patients with RH have multiple comorbidities, and need multiple drugs to control their BP. A decade ago, in a meta-analysis of more than 15,000 patients aged 62--76 years, Staessen et al[@b15-cia-9-1495] showed that treating isolated systolic hypertension substantially reduced morbidity and mortality rates. Another large-scale meta-analysis demonstrated the relevance of BP to cardiovascular mortality in the population aged 40--89 years, but the contribution of high BP to cardiovascular mortality decreases with advancing age.[@b16-cia-9-1495] Further, a 2011 meta-analysis of randomized controlled trials in hypertensive patients aged 75 years and older concluded that treatment reduced cardiovascular morbidity and mortality rates and the incidence of heart failure, even though the total mortality rate was not affected.[@b17-cia-9-1495] Opinion on treating the very elderly (≥80 years) was divided until the results of the Hypertension in the Very Elderly Trial[@b18-cia-9-1495] were published in 2008. This study documented major benefits of treatment in the very elderly age group as well.

To our knowledge, this is the first study showing a direct relationship between RH and AS by assessment of baPWV. We observed increased AS in patients with RH when compared with subjects who had controlled hypertension. This study showed that RH patients had greater numbers of risk factors than BP controlled patients, including diabetes mellitus, dyslipidemia, metabolic syndrome and baPWV. Multivariate logistic regression analysis showed that diabetes mellitus and baPWV were significantly related to the presence of RH. Other factors correlated negatively with the presence of RH. In two large studies, AS predicted future development of hypertension in normotensive subjects.

The first of these trials was the Atherosclerosis Risk in Communities study in middle-aged subjects (aged 45--64 years), in which 6,992 normotensive subjects were followed over 6 years.[@b19-cia-9-1495] AS was assessed by carotid artery diameter using high-resolution B-mode ultrasound and was found to significantly predict future hypertension. Each standard deviation increase in AS correlated with a 15% greater risk of future hypertension, independent of established risk factors and BP levels. However, this trial was criticized because of its nonadjusted analysis. Since most determinants of AS are also risk factors for hypertension, it is important to verify the predictive value of AS with regards to future hypertension remaining after adjustment for these risk factors.

The second trial assessed 2,571 normotensive subjects (aged 35--93 years) who were followed up for 4 years. AS was measured using aortic strain and distensibility parameters.[@b20-cia-9-1495] Aortic stiffness was determined by M-mode echocardiography using the polynomial regression analysis technique,[@b21-cia-9-1495] which calculated aortic systolic and diastolic diameters using standard equations for aortic strain, distensibility, and stiffness index (β). Aortic stiffness in normotensive individuals then predicted future hypertension after correcting for other risk factors by multiple linear regression modeling. This association was noted in both young and old subjects of both sexes.

AS occurs as a result of structural changes in connective tissue proteins within the endothelial and smooth muscle cells of the tunica media in the arterial wall, which are potentially related to the risk of development and progression of atherosclerosis.[@b22-cia-9-1495] The data from this study demonstrating increased baPWV also reflected stiffening as a result of structural changes in the arterial wall. AS related to hypertension is an insidious and progressive process, and is associated with numerous adverse hemodynamic effects and conditions associated with endothelial dysfunction.[@b6-cia-9-1495],[@b23-cia-9-1495],[@b24-cia-9-1495] It also sets up a vicious cycle whereby subtle early damage accelerates the rise in systolic pressure, causing further degeneration of aortic function.[@b25-cia-9-1495]--[@b27-cia-9-1495] This results in a mid-life rise in systolic pressure, subsequently progressing to both isolated systolic hypertension and resistant systolic hypertension.[@b28-cia-9-1495]--[@b30-cia-9-1495] Poorly controlled hypertension undoubtedly can lead to progressive vascular damage. This effect also sets up a further vicious cycle whereby increasing vascular stiffness leads to increased BP, thus contributing to further AS. This sets the stage for progressive worsening of hypertension and an increasing need for more BP medications.[@b29-cia-9-1495],[@b31-cia-9-1495] Accordingly, the current data support the hypothesis that progressive rigidity in the large arteries is characterized by progression from early to severe stages of hypertension that are difficult to control.[@b29-cia-9-1495],[@b31-cia-9-1495],[@b32-cia-9-1495] Recognition of this progression is clinically important, as it may allow vascular stiffness indexing to facilitate early identification of patients at risk of RH.

More recently, Daugherty et al[@b33-cia-9-1495] confirmed that there was a high rate of cardiovascular events (ie, death, myocardial infarction, heart failure, stroke, chronic kidney disease) in RH patients. Among 205,750 patients with hypertension found incidentally, 1.9% developed RH at a median of 1.5 years from the initial treatment. These RH patients were older, more often of male sex, and more frequently diabetic than patients who did not have RH. Cardiovascular event rates were significantly higher in RH patients as compared with non-RH patients (18.0% versus 13.5%, respectively; hazard ratio 1.47 \[CI 1.33--1.62\]; *P*\<0.001) after adjusting for patient and clinical characteristics.

Our study also demonstrated that diabetes mellitus is an independent risk factor for RH. RH represents an uncontrolled BP subset that is strongly associated with organ involvement, particularly at the cardiac, renal, and vascular levels.[@b35-cia-9-1495] The relationship between RH and cardiovascular disease/target organ damage may be bidirectional. RH may directly cause both development and worsening of target organ damage through persistent elevation of BP. Similarly, cardiovascular target organ damage may worsen the resistance to treatment, rendering hypertension even more difficult to control.[@b35-cia-9-1495],[@b36-cia-9-1495] The prevalence and incidence of RH is comparatively high in patients with renal disease, microvascular disease, left ventricular hypertrophy, aortic stiffness, or cerebrovascular disease, and in those with secondary hypertension. The findings of Dernellis and Panaretou,[@b20-cia-9-1495] as well as those of Liao et al[@b19-cia-9-1495] together with earlier studies, provide support for the bidirectional interaction of AS and hypertension. Numerous lifestyle and pharmacological interventions are effective for reducing AS. Furthermore, its early diagnosis with noninvasive techniques before development of RH or cardiovascular complications may identify individuals at risk at a time when lifestyle intervention may be useful.

Conclusion
==========

We have demonstrated that patients with RH have more elevated vascular stiffness than hypertensive patients with well controlled BP in older age. Thus, increases in baPWV, as demonstrated by AS, have a direct correlation with BP levels. It appears reasonable that strict BP control associated with reducing AS should be obtained to prevent severe functional and structural vascular changes during the hypertensive disease's course. We also propose that noninvasive modalities evaluating vascular stiffness (ie, baPWV) should be used in clinical practice to stratify cardiovascular risk.
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![Comparison of baPWV according to patient group. A significant baPWV increase was observed in the hypertensive groups (groups 2 and 3). Group 3 had the highest baPWV.\
**Abbreviations:** baPWV, brachial-ankle pulse wave velocity; CI, confidence interval.](cia-9-1495Fig1){#f1-cia-9-1495}

![ROC curve for baPWV versus the presence/absence of RH. The cut-off value for baPWV at 1,803 cm/sec had a sensitivity of 63.4% and a specificity of 67.2%, and an area under ROC curve of 0.687 for predicting RH.\
**Abbreviations:** ROC, receiver operating characteristic; baPWV, brachial-ankle pulse wave velocity; RH, resistant hypertension.](cia-9-1495Fig2){#f2-cia-9-1495}

###### 

Clinical characteristics of subjects

                           Group 1      Group 2                                                Group 3                                                                                           *P*-value
  ------------------------ ------------ ------------------------------------------------------ ------------------------------------------------------------------------------------------------- ----------------------------------------------------
  Subjects (n)             284          1,194                                                  142                                                                                               
  Male (%)                 71.8         59.0                                                   57.0                                                                                              \<0.001[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  Age (years)              67.0±3.8     67.3±4.7                                               68.3±3.3                                                                                          0.090
  BMI (kg/m^2^)            25.4±4.4     26.7±4.3[a](#tfn2-cia-9-1495){ref-type="table-fn"}     27.1±3.7[b](#tfn3-cia-9-1495){ref-type="table-fn"}                                                \<0.001[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  BSA (m^2^)               1.79±0.33    1.77±0.20                                              1.79±0.19                                                                                         0.357
  Diabetes (%)             6.7          22.4                                                   41.4                                                                                              \<0.001[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  Smoking (%)              3.5          13.7                                                   9.9                                                                                               \<0.001[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  Dyslipidemia (%)         19.1         48.5                                                   58.5                                                                                              \<0.001[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  CVA (%)                  0.7          1.5                                                    4.9                                                                                               0.004[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  COPD (%)                 0.4          1.8                                                    0.7                                                                                               0.126
  Metabolic syndrome (%)   4.5          31.4                                                   51.8                                                                                              \<0.001[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  LAE (%)                  1.0          4.7                                                    8.5                                                                                               0.028[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  LVH (%)                  6.2          9.8                                                    15.6                                                                                              0.018[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  SBP (mmHg)               126.6±14.8   138.2±18.2[a](#tfn2-cia-9-1495){ref-type="table-fn"}   152.3±21.2[b](#tfn3-cia-9-1495){ref-type="table-fn"},[c](#tfn4-cia-9-1495){ref-type="table-fn"}   \<0.001[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  DBP (mmHg)               73.8±9.8     79.9±11.1[a](#tfn2-cia-9-1495){ref-type="table-fn"}    84.9±12.1[b](#tfn3-cia-9-1495){ref-type="table-fn"},[c](#tfn4-cia-9-1495){ref-type="table-fn"}    \<0.001[\*](#tfn1-cia-9-1495){ref-type="table-fn"}
  baPWV (m/sec)            15.59±3.04   17.37±3.82[a](#tfn2-cia-9-1495){ref-type="table-fn"}   19.51±4.13[b](#tfn3-cia-9-1495){ref-type="table-fn"},[c](#tfn4-cia-9-1495){ref-type="table-fn"}   \<0.001[\*](#tfn1-cia-9-1495){ref-type="table-fn"}

**Notes:**

Denotes significant difference

*P*\<0.05 versus group 1

*P*\<0.05 versus group 1

*P*\<0.05 versus group 2. Data are expressed as mean ± standard deviation.

**Abbreviations:** BMI, body mass index; BSA, body surface area; CVA, cerebral vascular accident; COPD, chronic obstructive pulmonary disease; LAE, left atrium enlargement; LVH, left ventricular hypertrophy; SBP, systolic blood pressure; DBP, diastolic blood pressure; baPWV, brachial-ankle pulse wave velocity.

###### 

Laboratory findings

                            Group 1       Group 2                                                Group 3                                                *P*-value
  ------------------------- ------------- ------------------------------------------------------ ------------------------------------------------------ ----------------------------------------------------
  TC (mg/dL)                188.8±34.8    189.4±37.1                                             193.8±37.6                                             0.407
  HDL-C (mg/dL)             46.6±13.6     46.7±12.4                                              45.0±11.6                                              0.326
  LDL-C (mg/dL)             115.9±30.6    113.2±34.7                                             112.9±36.7                                             0.590
  Triglycerides (mg/dL)     150.9±141.3   156.6±119.3                                            181.5±127.2                                            0.062
  Creatinine (mg/dL)        1.1±0.4       1.2±1.3                                                1.3±1.4                                                0.210
  eGFR (mL/min/1.73 m^2^)   68.3±13.6     69.0±22.0                                              63.8±20.3                                              0.063
  Uric acid (mg/dL)         6.7±4.5       6.6±2.3                                                7.1±1.6                                                0.166
  Hemoglobin (g/dL)         14.8±1.5      14.1±4.4                                               13.7±2.0[b](#tfn8-cia-9-1495){ref-type="table-fn"}     0.027[\*](#tfn6-cia-9-1495){ref-type="table-fn"}
  HbA~1C~ (%)               8.26±2.15     7.75±1.81                                              7.70±1.93                                              0.497
  LVEDD (mm)                46.8±5.2      48.1±6.1[a](#tfn7-cia-9-1495){ref-type="table-fn"}     48.8±6.5[b](#tfn8-cia-9-1495){ref-type="table-fn"}     0.012[\*](#tfn6-cia-9-1495){ref-type="table-fn"}
  LVESD (mm)                27.2±4.5      28.3±6.4                                               29.2±6.4[b](#tfn8-cia-9-1495){ref-type="table-fn"}     0.024[\*](#tfn6-cia-9-1495){ref-type="table-fn"}
  EF (%)                    72.7±6.8      71.4±10.8                                              71.0±10.5                                              0.307
  IVSD (mm)                 11.7±2.2      12.0±2.9                                               12.5±3.3[b](#tfn8-cia-9-1495){ref-type="table-fn"}     0.042[\*](#tfn6-cia-9-1495){ref-type="table-fn"}
  PWD (mm)                  10.3±1.8      9.7±3.4                                                10.0±2.6                                               0.079
  LA (mm)                   37.4±5.2      37.4±5.6                                               38.5±6.4                                               0.087
  AO (mm)                   33.0±3.8      32.0±4.3[a](#tfn7-cia-9-1495){ref-type="table-fn"}     32.6±4.1                                               0.012[\*](#tfn6-cia-9-1495){ref-type="table-fn"}
  LVMI (g/m^2^)             58.0±55.9     103.2±71.6[a](#tfn7-cia-9-1495){ref-type="table-fn"}   112.9±51.2[b](#tfn8-cia-9-1495){ref-type="table-fn"}   \<0.001[\*](#tfn6-cia-9-1495){ref-type="table-fn"}

**Notes:**

Denotes significant difference

*P*\<0.05 versus group 1

*P*\<0.05 versus group 1. Data are expressed as mean ± standard deviation.

**Abbreviations:** TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; HbA~1C~, glycated hemoglobin; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; EF, ejection fraction; IVSD, interventricular septum diameter; PWD, posterior wall diameter; LA, left atrium; AO, aortic root; LVMI, left ventricular mass index.

###### 

Components of antihypertensive and antihyperlipidemic drugs

                                 Group 1   Group 2   Group 3   *P*-value
  ------------------------------ --------- --------- --------- -----------------------------------------------------
  **Antihypertensive drugs**                                   
  Diuretics (%)                  0         13.3      57.0      \<0.001[\*](#tfn10-cia-9-1495){ref-type="table-fn"}
  CCB (%)                        0         44.5      81.7      \<0.001[\*](#tfn10-cia-9-1495){ref-type="table-fn"}
  ACEI (%)                       0         7.8       9.9       0.239
  ARB (%)                        0         58.7      81.0      \<0.001[\*](#tfn10-cia-9-1495){ref-type="table-fn"}
  Beta-blocker (%)               0         32.8      62.0      \<0.001[\*](#tfn10-cia-9-1495){ref-type="table-fn"}
  Alpha-blocker (%)              0         3.6       26.1      \<0.001[\*](#tfn10-cia-9-1495){ref-type="table-fn"}
  Others (%)                     0         2.6       2.9       0.974
  **Antihyperlipidemic drugs**                                 
  Statin (%)                     2.8       22.7      29.6      \<0.001[\*](#tfn10-cia-9-1495){ref-type="table-fn"}
  Fenofibrate (%)                0         4.9       12        \<0.001[\*](#tfn10-cia-9-1495){ref-type="table-fn"}

**Note:**

Denotes significant difference.

**Abbreviations:** CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

###### 

Multivariate logistic regression analysis of factors related to patients with blood pressure control

                           Group 1   Group 3                                                                                     
  ------------------------ --------- --------------- --------------------------------------------------- ------- --------------- ---------------------------------------------------
  Male (%)                 1.365     0.871--2.140    0.175                                               1.233   0.460--1.429    0.468
  Age (years)              0.974     0.896--1.058    0.535                                               0.989   0.960--1.019    0.459
  BMI (kg/m^2^)            0.821     0.463--1.455    0.499                                               0.929   0.983--1.101    0.394
  BSA (m^2^)               1.461     0.295--7.232    0.804                                               1.049   0.146--7.526    0.962
  Diabetes (%)             1.621     0.259--10.129   0.606                                               2.114   1.194--3.744    0.010[\*](#tfn12-cia-9-1495){ref-type="table-fn"}
  Smoking (%)              1.965     0.379--10.183   0.421                                               0.578   0.260--1.286    0.179
  Dyslipidemia (%)         1.187     0.260--5.421    0.825                                               1.025   0.608--1.729    0.926
  CVA (%)                  1.117     0.242--5.515    0.887                                               3.478   0.979--11.717   0.054
  COPD (%)                 0.421     0.105--1.680    0.221                                               0.549   0.060--5.044    0.596
  Metabolic syndrome (%)   0.369     0.058--2.882    0.982                                               1.366   0.719--2.598    0.341
  LAE (%)                  1.376     0.593--3.189    0.903                                               1.061   0.373--3.023    0.911
  LVH (%)                  1.539     0.839--2.823    0.829                                               0.971   0.454--2.268    0.971
  SBP (mmHg)               0.915     0.839--0.997    0.043[\*](#tfn12-cia-9-1495){ref-type="table-fn"}   1.032   1.012--1.053    0.001[\*](#tfn12-cia-9-1495){ref-type="table-fn"}
  DBP (mmHg)               1.053     0.936--1.185    0.389                                               0.986   0.953--1.020    0.408
  baPWV (m/sec)            1.157     0.898--1.490    0.258                                               1.084   1.016--1.156    0.015[\*](#tfn12-cia-9-1495){ref-type="table-fn"}

**Note:**

Denotes significant difference.

**Abbreviations:** BMI, body mass index; CI, confidence interval; BSA, body surface area; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disease; LAE, left atrium enlargement; LVH, left ventricular hypertrophy; OR, odds ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; baPWV, brachial-ankle pulse wave velocity.

###### 

Multivariate logistic regression analysis of factors related to patients with blood pressure control

                          Group 1   Group 3                                        
  ----------------------- --------- --------------- ------- ------- -------------- -------
  TC (mg/dL)              1.010     0.981--1.039    0.516   1.017   1.000--1.034   0.051
  HDL-C (mg/dL)           0.955     0.882--1.034    0.256   0.993   0.964--1.023   0.649
  LDL-C (mg/dL)           1.006     0.981--1.032    0.637   0.986   0.970--1.002   0.089
  Triglycerides (mg/dL)   1.001     0.996--1.006    0.831   0.998   0.995--1.001   0.198
  Creatinine              0.831     0.239--2.893    0.771   0.905   0.723--1.132   0.382
  eGFR                    0.992     0.914--1.076    0.840   1.001   0.980--1.021   0.958
  Uric acid               0.997     0.594--1.675    0.992   1.060   0.984--1.142   0.125
  Hemoglobin (g/dL)       0.991     0.908--1.082    0.844   0.981   0.865--1.112   0.762
  LVEDD (mm)              1.595     0.625--4.071    0.328   0.965   0.997--1.299   0.438
  LVESD (mm)              0.870     0.609--1.244    0.447   1.138   0.930--1.106   0.055
  EF (%)                  0.968     0.850--1.102    0.623   1.074   0.986--1.146   0.053
  IVSD (mm)               2.393     0.393--14.559   0.343   0.982   0.876--1.102   0.761
  PWD (mm)                0.866     0.676--1.110    0.255   1.017   0.825--1.254   0.874
  LA (mm)                 1.018     0.874--1.185    0.819   0.993   0.946--1.042   0.782
  AO (mm)                 1.010     0.811--1.258    0.928   1.043   0.977--1.114   0.206
  LVMI (g/m^2^)           0.866     0.676--1.110    0.255   0.999   0.987--1.011   0.812
  HbA~1C~                 0.955     0.823--1.123    0.954   0.821   0.603--1.118   0.211

**Abbreviations:** CI, confidence interval; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; LVEDD, left ventricular end diastolic diameter; LVESD, left ventricular end systolic diameter; EF, ejection fraction; IVSD, interventricular septum diameter; PWD, posterior wall diameter; LA, left atrium; AO, aortic root; LVMI, left ventricular mass index; HbA~1C~, glycated hemoglobin; OR, odds ratio.
